glp-1 obesity drug news today september 29 2025 Alarming rise in weight loss overdoses How to Invest in GLP-1
Description
The FDA flagged marketing claims suggesting that compounded GLP-1s shared the same safety and efficacy profiles as their branded counterparts, noting that such labeling can mislead consumers and violate the Food, Drug, and Cosmetic Act
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinsons disease, finds a new study led by UCL researchers.
Personalized dosing, transparent pricingin person or by telehealth.
Several new weight loss treatments are in development, including Amgen's MariTide
